Royalty Pharma Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Royalty Pharma han disminuido a una tasa media anual de -39.2%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 10.4% anualmente. Los ingresos han ido creciendo a una tasa media de 5.7% al año. La rentabilidad financiera de Royalty Pharma es de 16.9%, y sus márgenes netos son de 48.2%.

Información clave

-39.2%

Tasa de crecimiento de los beneficios

-101.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	5.7%
Rentabilidad financiera	16.9%
Margen neto	48.2%
Próxima actualización de resultados	09 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Royalty Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

MUN:RPD Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	2,355	1,135	250	52
30 Sep 23	2,324	184	264	102
30 Jun 23	2,361	255	257	77
31 Mar 23	2,359	332	261	77
31 Dec 22	2,237	43	227	177
30 Sep 22	2,247	507	200	230
30 Jun 22	2,259	466	198	295
31 Mar 22	2,278	602	191	298
31 Dec 21	2,289	620	183	200
30 Sep 21	2,286	783	187	104
30 Jun 21	2,239	972	189	19
31 Mar 21	2,195	493	187	21
31 Dec 20	2,122	495	182	26
30 Sep 20	2,008	1,745	155	34
30 Jun 20	1,934	1,863	130	52
31 Mar 20	1,880	2,052	117	68
31 Dec 19	1,814	2,349	103	83
31 Dec 18	1,795	1,378	62	393
31 Dec 17	1,598	1,210	106	118

Ingresos de calidad: RPD tiene un gran one-off gain de $318.0M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio (48.2%) de RPD son superiores a los del año pasado (1.9%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de RPD han disminuido en un 39.2% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de RPD en el último año (2549.5%) supera su media de 5 años (-39.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de RPD en el último año (2549.5%) superó al de la industria Pharmaceuticals 3.8%.

Royalty Pharma Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Recent updates

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Insufficient new directors

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold €2.1m worth of stock

Investor sentiment deteriorates as stock falls 17%

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

High number of new and inexperienced directors

Director recently sold €4.7m worth of stock

High number of new and inexperienced directors

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

High number of new and inexperienced directors

Royalty Pharma Announces Expansion of Senior Leadership Team

Director recently sold €15m worth of stock

High number of new and inexperienced directors

Upcoming dividend of US$0.19 per share

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.24 in 3Q 2021)

Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022

Royalty Pharma plc Announces Executive Changes

Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022

High number of new and inexperienced directors

Director recently sold €1.9m worth of stock

High number of new and inexperienced directors

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$1.08 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Royalty Pharma plc Declares Third Quarter 2022 Dividend, to Be Paid on September 15, 2022

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Investor sentiment improved over the past week

Royalty Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Director recently sold €1.2m worth of stock

Royalty Pharma plc Announces Directorate Change

High number of new and inexperienced directors

Director recently sold €5.6m worth of stock

Upcoming dividend of US$0.19 per share

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.18 in 1Q 2021)

High number of new and inexperienced directors

Royalty Pharma plc Declares Second Quarter 2022 Dividend, Payable on June 15, 2022

Royalty Pharma plc to Report Q1, 2022 Results on May 05, 2022

Director recently sold €2.1m worth of stock

High number of new and inexperienced directors

Lead Independent Director recently bought €1.1m worth of stock

High number of new and inexperienced directors

Director recently sold €2.6m worth of stock

High number of new and inexperienced directors

Insider recently sold €8.3m worth of stock

Investor sentiment improved over the past week

High number of new and inexperienced directors

Director recently sold €2.0m worth of stock

High number of new and inexperienced directors

Second quarter 2021 earnings released: EPS US$1.08 (vs US$1.25 in 2Q 2020)

Upcoming dividend of US$0.17 per share

Insider recently sold €9.5m worth of stock

Upcoming dividend of US$0.17 per share

Independent Director recently bought €984k worth of stock

Full year 2020 earnings released: EPS US$2.64

Revenue beats expectations

Royalty Pharma plc to Report Q4, 2020 Results on Feb 17, 2021

New 90-day high: €41.00

Desglose de ingresos y gastos
Beta